BR112015002371A2 - estirpes mutantes e usos do mesmo de neospora - Google Patents

estirpes mutantes e usos do mesmo de neospora

Info

Publication number
BR112015002371A2
BR112015002371A2 BR112015002371A BR112015002371A BR112015002371A2 BR 112015002371 A2 BR112015002371 A2 BR 112015002371A2 BR 112015002371 A BR112015002371 A BR 112015002371A BR 112015002371 A BR112015002371 A BR 112015002371A BR 112015002371 A2 BR112015002371 A2 BR 112015002371A2
Authority
BR
Brazil
Prior art keywords
neospora
mutant strains
function
protein
mutant
Prior art date
Application number
BR112015002371A
Other languages
English (en)
Other versions
BR112015002371A8 (pt
Inventor
Boussemart-Prouvost Anne-France
Seche Edouard
Lamarque Mauld
Breton Pascal
Morisse-Philippe Solen
Original Assignee
Vitamfero
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitamfero filed Critical Vitamfero
Publication of BR112015002371A2 publication Critical patent/BR112015002371A2/pt
Publication of BR112015002371A8 publication Critical patent/BR112015002371A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/10—Protozoa; Culture media therefor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/6893—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for protozoa
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

resumo “estirpes mutantes e usos do mesmo de neospora” a presente invenção concerne uma estirpe mutante de neospora spp, qui na função da proteína ncmic3 e / ou a função da proteína ncmic1 é suprimida, e as suas utilizações de uma composição farmacêutica ou de uma composição de vacina.
BR112015002371A 2012-08-02 2013-08-02 estirpes mutantes de neospora e o uso das mesmas BR112015002371A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1257544A FR2994193B1 (fr) 2012-08-02 2012-08-02 Souches mutantes de neospora et leurs utilisations
PCT/FR2013/051877 WO2014020291A2 (fr) 2012-08-02 2013-08-02 Souches mutantes de neospora et leurs utilisations

Publications (2)

Publication Number Publication Date
BR112015002371A2 true BR112015002371A2 (pt) 2017-08-01
BR112015002371A8 BR112015002371A8 (pt) 2018-01-16

Family

ID=47429869

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015002371A BR112015002371A8 (pt) 2012-08-02 2013-08-02 estirpes mutantes de neospora e o uso das mesmas

Country Status (11)

Country Link
US (1) US9603914B2 (pt)
EP (1) EP2880051B1 (pt)
CN (1) CN104822700B (pt)
AR (1) AR091980A1 (pt)
AU (1) AU2013298400B2 (pt)
BR (1) BR112015002371A8 (pt)
CA (1) CA2880867A1 (pt)
ES (1) ES2755952T3 (pt)
FR (1) FR2994193B1 (pt)
NZ (1) NZ705408A (pt)
WO (1) WO2014020291A2 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015175672A1 (en) 2014-05-14 2015-11-19 Merial, Inc. Methods for freeze-drying and rehydrating biologics

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2224210T3 (es) * 1996-11-12 2005-03-01 Pfizer Inc. Vacuna de neospora viva atenuada.
EP0953641A3 (en) * 1998-03-26 2002-03-13 Pfizer Products Inc. Polynucleotide molecules encoding neospora proteins
FR2864966B1 (fr) 2004-01-13 2006-05-05 Agronomique Inst Nat Rech Souches vaccinales d'apicomplexes de la famille des sarcocystidae.

Also Published As

Publication number Publication date
AR091980A1 (es) 2015-03-11
ES2755952T3 (es) 2020-04-24
NZ705408A (en) 2017-12-22
CN104822700A (zh) 2015-08-05
AU2013298400B2 (en) 2017-12-21
CN104822700B (zh) 2018-04-27
FR2994193B1 (fr) 2016-05-20
FR2994193A1 (fr) 2014-02-07
EP2880051B1 (fr) 2019-10-09
CA2880867A1 (fr) 2014-02-06
EP2880051A2 (fr) 2015-06-10
AU2013298400A1 (en) 2015-03-12
WO2014020291A3 (fr) 2014-03-27
WO2014020291A2 (fr) 2014-02-06
BR112015002371A8 (pt) 2018-01-16
US20150190487A1 (en) 2015-07-09
US9603914B2 (en) 2017-03-28

Similar Documents

Publication Publication Date Title
BR112018077266A2 (pt) composições compreendendo cepas bacterianas
MA47664A1 (fr) Anticorps anti-c10orf54 et leurs utilisations
CO2017009150A2 (es) Composiciones para el cuidado oral que comprenden arginina o lisina, óxido de zinc, una fuente de fluoruro y un abrasivo de sílice
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
MA34881B1 (fr) Anticorps et immunoconjugués anti-mésothéline
MA39095A1 (fr) Anticorps et immunoconjugués anti-cd33
MA37538A2 (fr) Anticorps et immunoconjugués anti-ly6e et procédés d'utilisation
MA37840A3 (fr) Immunoconjugués comprenant des anticorps anti-cd79b
BR112015015225A2 (pt) escova de dentes elétrica com um sensor de pressão
BR112014031310A2 (pt) anticorpos anti-pcsk9, formulações, dosagem e métodos de uso
MA38686A1 (fr) Anticorps anti-acide téichoïque de la paroi cellulaire et conjugués associés
BR112016006048A8 (pt) composições antimicrobianas
MA38273A1 (fr) Thérapie de combinaison avec des anticorps anti-her3
EP3878445A3 (en) Acamprosate formulations, methods of using the same, and combinations comprising the same
BR112015004515A2 (pt) composição imunogênica
BR112014032636A2 (pt) Vacinas atenuadas de streptococcus suis e métodos de produção e usos das mesmas
BR112015006731A2 (pt) combinações e usos das mesmas
MA44550B1 (fr) Anticorps anti-acide téichoique de la paroi cellulaire et conjugués associés
BR112014013876A2 (pt) vacina à base de toxina de clostridium difficile
NZ701463A (en) Anti-phytopathogenic composition
BR112015002371A2 (pt) estirpes mutantes e usos do mesmo de neospora
MX2014006574A (es) Formulaciones de acamprosato, metodos de uso de las mismas, y combinaciones que comprenden las mismas.
BR112014016804A8 (pt) composições, métodos de uso e métodos de tratamento
IN2014MN01382A (pt)
MA40805A (fr) Compositions pharmaceutiques à action prolongée contre l'hépatite c

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements